HK1204261A1 - Immunogenic wt-1 peptides and methods of use thereof wt-1 - Google Patents
Immunogenic wt-1 peptides and methods of use thereof wt-1Info
- Publication number
- HK1204261A1 HK1204261A1 HK15104710.4A HK15104710A HK1204261A1 HK 1204261 A1 HK1204261 A1 HK 1204261A1 HK 15104710 A HK15104710 A HK 15104710A HK 1204261 A1 HK1204261 A1 HK 1204261A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- immunogenic
- peptides
- methods
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261586177P | 2012-01-13 | 2012-01-13 | |
US201261647207P | 2012-05-15 | 2012-05-15 | |
PCT/US2013/021448 WO2013106834A2 (en) | 2012-01-13 | 2013-01-14 | Immunogenic wt-1 peptides and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1204261A1 true HK1204261A1 (en) | 2015-11-13 |
Family
ID=48782099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15104710.4A HK1204261A1 (en) | 2012-01-13 | 2015-05-18 | Immunogenic wt-1 peptides and methods of use thereof wt-1 |
Country Status (8)
Country | Link |
---|---|
US (3) | US20150104413A1 (ja) |
EP (2) | EP2802347B1 (ja) |
JP (2) | JP6282598B2 (ja) |
CN (2) | CN104684577B (ja) |
AU (2) | AU2013207669C1 (ja) |
CA (1) | CA2861206C (ja) |
HK (1) | HK1204261A1 (ja) |
WO (1) | WO2013106834A2 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2802347B1 (en) | 2012-01-13 | 2019-01-09 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
EP3640375A3 (en) | 2012-12-11 | 2020-07-29 | Albert Einstein College of Medicine | Methods for high throughput receptor/ligand identification |
WO2015164826A2 (en) * | 2014-04-24 | 2015-10-29 | Rhode Island Hospital | ASPARTATE-β-HYDROXYLASE INDUCES EPITOPE-SPECIFIC T CELL RESPONSES IN TUMORS |
JP6770269B2 (ja) * | 2015-06-25 | 2020-10-14 | 国立大学法人神戸大学 | 経口腫瘍ワクチン |
AU2016320877A1 (en) * | 2015-09-10 | 2018-04-19 | Memorial Sloan Kettering Cancer Center | Methods of treating multiple myeloma and plasma cell leukemia by T cell therapy |
EP3362929B1 (en) * | 2015-10-12 | 2020-08-12 | Nantomics, LLC | Viral neoepitopes and uses thereof |
US11033613B2 (en) * | 2015-11-20 | 2021-06-15 | Memorial Sloan Kettering Cancer Center | Methods and compositions for treating cancer |
SG11201808552XA (en) | 2016-05-18 | 2018-10-30 | Cue Biopharma Inc | T-cell modulatory multimeric polypeptides and methods of use thereof |
IL262606B2 (en) | 2016-05-18 | 2023-04-01 | Albert Einstein College Medicine Inc | pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them |
MX2019005685A (es) | 2016-11-30 | 2019-09-04 | Advaxis Inc | Composiciones inmunogenicas contra mutaciones de cancer recurrentes y metodos de uso de las mismas. |
IL297617B2 (en) | 2016-12-22 | 2023-11-01 | Cue Biopharma Inc | Multimeric polypeptides modulate T cells and methods for their use |
EP3523332B1 (en) | 2017-01-06 | 2021-12-29 | Eutilex Co., Ltd. | Anti-human 4-1 bb antibodies and use thereof |
EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE |
KR102619015B1 (ko) | 2017-03-15 | 2023-12-28 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
JP2020534352A (ja) | 2017-09-07 | 2020-11-26 | キュー バイオファーマ,インコーポレーテッド | コンジュゲーション部位を有するt細胞調節多量体ポリペプチド及びその使用方法 |
WO2019094607A2 (en) * | 2017-11-08 | 2019-05-16 | Advaxis, Inc. | Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof |
EP3737689A4 (en) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF |
CN112261947A (zh) * | 2018-05-25 | 2021-01-22 | 威斯塔研究所 | 肿瘤特异性新抗原和其使用方法 |
WO2020132366A2 (en) * | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
CN110423723A (zh) * | 2019-07-18 | 2019-11-08 | 南方医科大学南方医院 | 一种外周血b细胞系的构建方法及其应用 |
JP2023508726A (ja) | 2019-12-31 | 2023-03-03 | エリクサージェン セラピューティクス,インコーポレイティド | 細胞及び組織への核酸及びタンパク質の温度ベースの一過性送達 |
JP2023526723A (ja) | 2020-05-12 | 2023-06-23 | キュー バイオファーマ, インコーポレイテッド | 多量体t細胞調節性ポリペプチド及びその使用方法 |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA8748A (en) | 1878-05-04 | George W. Ainsworth | Improvements on clothes dryers | |
CA23766A (en) | 1886-04-06 | Albert M. Todd | Process of, and appartus for treating essential oils to obtain the concrete or crystalline part thereof separate and apart from the liquid portion | |
CA59350A (en) | 1898-02-26 | 1898-03-19 | Thomas Henry Simmonds | Brake for velocipede, tricycle, etc. |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5837249A (en) | 1985-04-19 | 1998-11-17 | The Wistar Institute | Method for generating an immunogenic T cell response protective against a virus |
US5726288A (en) | 1989-11-13 | 1998-03-10 | Massachusetts Institute Of Technology | Localization and characterization of the Wilms' tumor gene |
US5229115A (en) | 1990-07-26 | 1993-07-20 | Immunex Corporation | Adoptive immunotherapy with interleukin-7 |
AU1570292A (en) | 1991-02-07 | 1992-09-07 | Board Of Trustees Of The University Of Illinois, The | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
WO1994021287A1 (en) | 1993-03-15 | 1994-09-29 | The Government Of The United States Of America As Represented By The Department Of Health And Human Services | Peptide coated dendritic cells as immunogens |
WO1995029240A1 (en) | 1994-04-22 | 1995-11-02 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Isolation and characterization of a novel primate t-cell lymphotropic virus and the use of this virus or components thereof in diagnostics assays and vaccines |
US5622835A (en) | 1994-04-28 | 1997-04-22 | The Wistar Institute Of Anatomy & Biology | WT1 monoclonal antibodies |
US5643786A (en) | 1995-01-27 | 1997-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for isolating dendritic cells |
US6156316A (en) | 1995-05-08 | 2000-12-05 | Sloan-Kettering Institute For Cancer Research | Oncogene fusion protein peptide vaccines |
JPH11171896A (ja) | 1995-09-19 | 1999-06-29 | Kirin Brewery Co Ltd | 新規ペプチド化合物およびその医薬組成物 |
US5981217A (en) | 1995-12-11 | 1999-11-09 | Mayo Foundation For Medical Education And Research | DNA encoding TGF-β inducible early factor-1 (TIEF-1), a gene expressed by osteoblasts |
AU1394497A (en) | 1996-01-17 | 1997-08-11 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
US6207375B1 (en) | 1996-12-11 | 2001-03-27 | Mayo Foundation For Medical Educational & Research | TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer |
ID27813A (id) | 1998-01-28 | 2001-04-26 | Corixa Corp | Senyawa-senyawa untuk terapi dan diagnosa kanker paru-paru dan metoda untuk penggunaannya |
DK1103564T3 (da) | 1998-07-31 | 2009-05-11 | Int Inst Cancer Immunology Inc | Cancerantigener baseret på tumorsuppressorgen WT1-produkt |
US7115272B1 (en) | 1998-09-30 | 2006-10-03 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7655249B2 (en) | 1998-09-30 | 2010-02-02 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7329410B1 (en) | 1998-09-30 | 2008-02-12 | Corixa Corporation | Compositions and method for WT1 specific immunotherapy |
US20030072767A1 (en) | 1998-09-30 | 2003-04-17 | Alexander Gaiger | Compositions and methods for WT1 specific immunotherapy |
US7901693B2 (en) | 1998-09-30 | 2011-03-08 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7144581B2 (en) | 2000-10-09 | 2006-12-05 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7063854B1 (en) * | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
US20120301492A1 (en) | 1998-09-30 | 2012-11-29 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
GB9823897D0 (en) | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
AU1675900A (en) | 1998-12-22 | 2000-07-12 | Genset | Complementary dna's encoding proteins with signal peptides |
AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
WO2000054839A2 (en) | 1999-03-15 | 2000-09-21 | Introgen Therapeutics, Inc. | Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses |
US6593299B1 (en) * | 1999-04-21 | 2003-07-15 | University Of Florida Research Foundation, Inc. | Compositions and methods for controlling pests |
AU7859900A (en) | 1999-10-04 | 2001-05-10 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
CA2401070A1 (en) * | 2000-02-22 | 2001-08-30 | Corixa Corporation | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
US20030082194A1 (en) | 2000-02-22 | 2003-05-01 | Alexander Gaiger | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
US6861234B1 (en) | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
EP1209226A3 (en) | 2000-11-07 | 2002-06-05 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70) |
JP3728439B2 (ja) | 2001-03-22 | 2005-12-21 | 治夫 杉山 | Wt1改変ペプチド |
US8771702B2 (en) | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
CN1320923C (zh) | 2001-06-29 | 2007-06-13 | 中外制药株式会社 | 含有基于癌抑制基因wt1的产物的癌抗原和阳离子脂质体的癌疫苗 |
US7553494B2 (en) | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
US20050002951A1 (en) | 2001-09-28 | 2005-01-06 | Haruo Sugiyama | Novel method of inducing antigen-specific t cells |
WO2003028757A1 (fr) | 2001-09-28 | 2003-04-10 | Haruo Sugiyama | Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes |
US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
US20030175272A1 (en) | 2002-03-07 | 2003-09-18 | Medcell Biologics, Inc. | Re-activated T-cells for adoptive immunotherapy |
CN100408683C (zh) | 2002-06-12 | 2008-08-06 | 株式会社国际癌症免疫研究所 | Hla-a24限制性癌抗原肽 |
AU2004224425B2 (en) | 2003-02-06 | 2010-06-24 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
US20050008618A1 (en) | 2003-02-27 | 2005-01-13 | Howard Kaufman | Composition for delivering an agent to a target cell and uses thereof |
WO2004111075A2 (en) * | 2003-03-05 | 2004-12-23 | Dendreon Corporation | Alternative reading frame polypeptides for treatment |
CA2893995A1 (en) | 2003-06-27 | 2005-01-06 | International Institute Of Cancer Immunology, Inc. | Method of diagnosis of cancer |
US20050147621A1 (en) | 2003-10-10 | 2005-07-07 | Higgins Darren E. | Use of bacterial 5' untranslated regions for nucleic acid expression |
CN101580538B (zh) | 2003-11-05 | 2013-06-19 | 株式会社国际癌症免疫研究所 | Wt1衍生的hla-dr-结合抗原肽 |
JP2007516966A (ja) * | 2003-12-01 | 2007-06-28 | スローン−ケターリング インスティチュート フォー キャンサー リサーチ | 合成hla結合ペプチド類似体及びその使用方法 |
ES2324538T3 (es) | 2003-12-05 | 2009-08-10 | Multimmune Gmbh | Anticuerpos anti-hsp terapeuticos y de diagnostico. |
EP1550458A1 (en) | 2003-12-23 | 2005-07-06 | Vectron Therapeutics AG | Synergistic liposomal adjuvants |
US20050260217A1 (en) | 2004-03-04 | 2005-11-24 | Corixa Corporation | Co-encapsulated WT1 polypeptide and immunostimulant microsphere formulations and methods thereof |
US20050214268A1 (en) | 2004-03-25 | 2005-09-29 | Cavanagh William A Iii | Methods for treating tumors and cancerous tissues |
US20050221481A1 (en) | 2004-03-30 | 2005-10-06 | Istituto Superiore Di Sanita' | Amplification of T cells from human cord blood in serum-deprived culture stimulated with stem cell factor, interleukin-7 and interleukin-2 |
PL1731605T3 (pl) | 2004-03-31 | 2010-08-31 | Int Inst Cancer Immunology Inc | Nowotworowe peptydy antygenowe pochodzące z WT1 |
US9629927B2 (en) | 2005-07-29 | 2017-04-25 | Sloan-Kettering Institute For Cancer Research | Single wall nanotube constructs and uses thereof |
ES2531142T3 (es) | 2005-10-17 | 2015-03-11 | Sloan Kettering Inst Cancer | Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden |
BRPI0619255B8 (pt) * | 2005-11-30 | 2021-05-25 | Chugai Seiyaku Kabishiki Kaisha | composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer |
DK1988163T3 (da) | 2006-02-22 | 2012-08-20 | Int Inst Cancer Immunology Inc | Hla-a*3303-begrænset wt1 peptid og farmaceutisk sammensætning omfattende det samme |
ES2387999T3 (es) | 2006-03-29 | 2012-10-05 | International Institute Of Cancer Immunology, Inc. | ARNsi específico de la isoforma WT1 17AA(-) y uso del mismo |
CA2645766A1 (en) | 2006-04-10 | 2007-10-25 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and methods of use thereof |
WO2007120603A2 (en) | 2006-04-10 | 2007-10-25 | Sloan Kettering Institute For Cancer Research | Immunogenic bcr-abl peptides and methods of use thereof |
JP5623747B2 (ja) | 2006-12-27 | 2014-11-12 | エモリー ユニバーシティ | 感染症および腫瘍を処置するための組成物および方法 |
WO2008081701A1 (ja) | 2006-12-28 | 2008-07-10 | International Institute Of Cancer Immunology, Inc. | Hla-a*1101拘束性wt1ペプチド、およびそれを含む医薬組成物 |
JP5239041B2 (ja) | 2007-02-07 | 2013-07-17 | 一般財団法人阪大微生物病研究会 | 癌の治療剤 |
DK2119778T3 (en) | 2007-02-27 | 2016-01-25 | Int Inst Cancer Immunology Inc | A process for the activation of the helper T cell, and composition for use in this process |
AR066676A1 (es) | 2007-05-24 | 2009-09-02 | Glaxosmithkline Biolog Sa | Composicion antigenica liofilizada que contiene un agonista del receptor tipo toll |
KR100995340B1 (ko) | 2007-11-19 | 2010-11-19 | 재단법인서울대학교산학협력재단 | 자연 살해 t 세포의 리간드와 항원을 적재한 단핵구 또는미분화 골수성 세포를 포함하는 백신 |
EP3384926A1 (en) | 2007-12-05 | 2018-10-10 | International Institute of Cancer Immunology, Inc. | Cancer vaccine composition |
KR100900837B1 (ko) | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물 |
JP2011523553A (ja) | 2008-05-19 | 2011-08-18 | アデュロ バイオテック | PrfA*変異株リステリアを含む組成物およびその使用法 |
WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
WO2011059835A2 (en) | 2009-11-11 | 2011-05-19 | Quest Diagnostics Investments Incorporated | Wt1 mutations for prognosis of myeloproliferative disorders |
US20110136141A1 (en) | 2009-12-03 | 2011-06-09 | Abbott Laboratories | Peptide reagents and method for inhibiting autoantibody antigen binding |
WO2011100754A1 (en) | 2010-02-15 | 2011-08-18 | The Trustees Of The University Of Pennsylvania | Live listeria-based vaccines for central nervous system therapy |
CA2809362C (en) | 2010-08-24 | 2020-03-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Educatn | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
AU2011313327B2 (en) | 2010-10-05 | 2015-10-22 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
AP2013007158A0 (en) | 2011-03-11 | 2013-10-31 | Gilead Calistoga Llc | Combination therapies for hematologic malignancies |
CA2839663A1 (en) | 2011-06-28 | 2013-01-03 | International Institute Of Cancer Immunology, Inc. | Receptor gene for peptide cancer antigen-specific t cell |
US9783821B2 (en) | 2011-07-29 | 2017-10-10 | Riken | Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct |
US9539299B2 (en) | 2011-10-27 | 2017-01-10 | International Institute Of Cancer Immunology, Inc. | Combination therapy with WT1 peptide vaccine and temozolomide |
EP2792745B1 (en) | 2011-12-14 | 2017-11-15 | National University Corporation Kochi University | Modification of helper t cell-inducing polypeptide |
EP2802347B1 (en) | 2012-01-13 | 2019-01-09 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
EP2844743B1 (en) | 2012-05-03 | 2021-01-13 | Fred Hutchinson Cancer Research Center | Enhanced affinity t cell receptors and methods for making the same |
WO2014007266A1 (ja) | 2012-07-02 | 2014-01-09 | 大日本住友製薬株式会社 | 癌抗原ペプチド経皮剤 |
CN105007930B (zh) | 2012-10-23 | 2018-08-17 | 优比维克有限责任公司 | 用于治疗疾病的同种异体自噬体富集组合物 |
TWI646970B (zh) | 2012-12-17 | 2019-01-11 | 大塚製藥股份有限公司 | 活化輔助t細胞的方法 |
WO2014103310A1 (ja) | 2012-12-26 | 2014-07-03 | バイオコモ株式会社 | ヒトパラインフルエンザ2型ウイルスベクターを利用したワクチン |
US9919037B2 (en) | 2013-01-15 | 2018-03-20 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
CA2840988A1 (en) | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Wt1 peptide cancer vaccine composition for mucosal administration |
IN2014CH00393A (ja) | 2013-02-05 | 2015-04-03 | Nitto Denko Corp | |
IN2014CH00391A (ja) | 2013-02-05 | 2015-04-03 | Nitto Denko Corp | |
EP2762152A1 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | WT1 peptide cancer vaccine composition for transdermal administration |
WO2014127296A1 (en) | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd | Cancer vaccines and vaccination methods |
JP6294868B2 (ja) | 2013-03-12 | 2018-03-14 | 大日本住友製薬株式会社 | 液体水性組成物 |
EP3607974A1 (en) | 2013-03-15 | 2020-02-12 | The Trustees of The University of Pennsylvania | Cancer vaccines and methods of treatment using the same |
DK2982681T3 (en) | 2013-03-29 | 2018-12-10 | Sumitomo Dainippon Pharma Co Ltd | WT1 ANTIGENPEPTIDKONJUGATVACCINE |
SG11201508521SA (en) | 2013-04-25 | 2015-11-27 | Vaximm Ag | Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1 |
CA2912514A1 (en) | 2013-05-13 | 2014-11-20 | International Institute Of Cancer Immunology, Inc. | Method for predicting clinical effect of immunotherapy |
WO2015002134A1 (ja) | 2013-07-02 | 2015-01-08 | 公益財団法人がん研究会 | 細胞性免疫誘導ワクチン |
CA2930847A1 (en) | 2013-11-22 | 2015-05-28 | Fred Hutchinson Cancer Research Center | Engineered high-affinity human t cell receptors |
HUE045567T2 (hu) | 2013-12-18 | 2020-01-28 | Vaximm Gmbh | MSLN-t célzó DNS vakcina rák immunterápiához |
WO2015103602A1 (en) | 2014-01-06 | 2015-07-09 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
BR112016018521A2 (pt) | 2014-02-14 | 2017-10-17 | Immune Design Corp | composição, e, kit. |
WO2015129790A1 (ja) | 2014-02-26 | 2015-09-03 | 株式会社バイオイミュランス | Wt1抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤 |
US10023841B2 (en) | 2014-05-23 | 2018-07-17 | Baylor Research Institute | Methods and compositions for treating breast cancer with dendritic cell vaccines |
CA2970236A1 (en) | 2014-12-11 | 2016-06-16 | International Institute Of Cancer Immunology, Inc. | Compositions comprising wt1 peptide for immunotherapy of angiogenic disease |
JP6770269B2 (ja) | 2015-06-25 | 2020-10-14 | 国立大学法人神戸大学 | 経口腫瘍ワクチン |
WO2017049074A1 (en) | 2015-09-18 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucleotide formulations for use in the treatment of renal diseases |
-
2013
- 2013-01-14 EP EP13736176.2A patent/EP2802347B1/en active Active
- 2013-01-14 AU AU2013207669A patent/AU2013207669C1/en active Active
- 2013-01-14 CA CA2861206A patent/CA2861206C/en active Active
- 2013-01-14 EP EP18215878.2A patent/EP3520810A3/en active Pending
- 2013-01-14 CN CN201380014022.7A patent/CN104684577B/zh active Active
- 2013-01-14 CN CN201810342393.2A patent/CN108676069A/zh active Pending
- 2013-01-14 WO PCT/US2013/021448 patent/WO2013106834A2/en active Application Filing
- 2013-01-14 US US14/372,174 patent/US20150104413A1/en not_active Abandoned
- 2013-01-14 JP JP2014552368A patent/JP6282598B2/ja active Active
-
2015
- 2015-05-18 HK HK15104710.4A patent/HK1204261A1/xx unknown
-
2017
- 2017-05-30 US US15/608,964 patent/US10100087B2/en active Active
-
2018
- 2018-01-24 JP JP2018009786A patent/JP6995645B2/ja active Active
- 2018-02-20 AU AU2018201210A patent/AU2018201210B2/en active Active
- 2018-09-07 US US16/125,213 patent/US10815274B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2861206C (en) | 2021-07-06 |
EP2802347A2 (en) | 2014-11-19 |
JP2018104438A (ja) | 2018-07-05 |
US20170334951A1 (en) | 2017-11-23 |
CA2861206A1 (en) | 2013-07-18 |
AU2018201210B2 (en) | 2020-04-09 |
AU2013207669B9 (en) | 2017-12-14 |
JP6282598B2 (ja) | 2018-02-21 |
US10815274B2 (en) | 2020-10-27 |
AU2013207669B2 (en) | 2017-11-23 |
EP2802347B1 (en) | 2019-01-09 |
JP6995645B2 (ja) | 2022-01-14 |
US20150104413A1 (en) | 2015-04-16 |
WO2013106834A3 (en) | 2015-01-22 |
AU2018201210A1 (en) | 2018-03-08 |
WO2013106834A2 (en) | 2013-07-18 |
EP3520810A3 (en) | 2019-11-06 |
CN104684577A (zh) | 2015-06-03 |
AU2013207669C1 (en) | 2018-05-31 |
JP2015512866A (ja) | 2015-04-30 |
CN104684577B (zh) | 2018-05-08 |
AU2013207669A1 (en) | 2014-08-07 |
US20190092813A1 (en) | 2019-03-28 |
EP2802347A4 (en) | 2016-06-01 |
CN108676069A (zh) | 2018-10-19 |
EP3520810A2 (en) | 2019-08-07 |
US10100087B2 (en) | 2018-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1204261A1 (en) | Immunogenic wt-1 peptides and methods of use thereof wt-1 | |
HUE052541T2 (hu) | Immunogén WT-1 peptidek és eljárások azok alkalmazására | |
EP2912178A4 (en) | SUPER AMPLIFIER AND METHOD FOR USE THEREOF | |
HK1208439A1 (en) | 5-azaindazole compounds and methods of use 5- | |
HK1199892A1 (en) | Modified mini-hepcidin peptides and methods of using thereof | |
ZA201501858B (en) | Anti-mcam antibodies and associated methods of use | |
PT2925782T (pt) | Anticorpos anti-cd47 e métodos de utilização destes | |
ZA201405858B (en) | Recombinant microorganisms and methods of use thereof | |
EP2895083A4 (en) | LIGATOR AND METHOD FOR ITS USE | |
EP2870170A4 (en) | NOVEL PEPTIDES AND THEIR USE | |
IL238227A0 (en) | Antibodies against c16orf54 and uses thereof | |
HK1206037A1 (en) | Human antibodies to gfr3 and methods of use thereof gfr3 | |
HK1197187A1 (en) | Anti-lrp5 antibodies and methods of use lrp5 | |
EP2782589A4 (en) | ANTIMICROBIAL PEPTIDES AND METHOD FOR THEIR USE | |
HK1225645A1 (zh) | Pcv2b趨異株疫苗組合物以及使用方法 | |
EP2863858A4 (en) | PATIENT DISPOSAL SYSTEMS AND METHOD OF USE | |
EP2806811A4 (en) | VERTEBRAL CONSTRUCTION | |
HK1203161A1 (en) | Peptides and methods of using same | |
EP2938632A4 (en) | ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE | |
EP2897639A4 (en) | IMPROVED VACCINE COMPOSITIONS AND METHODS OF USE | |
EP2852397A4 (en) | HUWENTOXIN IV VARIANTS AND METHODS OF USE | |
HK1209432A1 (en) | Anti-jagged antibodies and methods of use | |
SG11201504805PA (en) | Porcine parvovirus 5a, methods of use and vaccine | |
EP2897680A4 (en) | INFLATION DEVICES AND APPLICATION METHOD | |
EP2925341A4 (en) | PEPTIDE COMPOUNDS AND METHODS OF MAKING AND USING THEM |